Covaxin effective against Delta Plus variant of Covid-19: ICMR Study

Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial

Covaxin effective against Delta Plus variant of Covid-19: ICMR Study

A vial of Covaxin | File Pic

Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in biorxivby the Indian Council of Medical and Research (ICMR).

"Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of Covid-19 naive individuals full doses of BBV152 vaccine, Covid-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.," the study said.

The recent emergence of the SARS-CoV-2 Variant B.1.617.2 (Delta) variant with its high transmissibility has led to the second wave in India.

Subsequently, Delta has further mutated to Delta AY.1, AY.2, and AY.3.

Of these, AY.1 variant was first detected in India in April 2021 and subsequently from 20 other countries as well, the study said.

The study is a pre-print and has not been peer reviewed.

Covaxin demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2per centprotection against the B.1.617.2 Delta variant, Bharat Biotech had said while concluding the final analysis of Covaxin efficacy from Phase3 trials on July 3.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels